Several recent studies not only linked this role of EZH2 to HCC development but also bridged its pro-oncogenic function to the decrease of PD-L1 and shaping of tumor immunosuppressive microenvironment, suggesting that HCC patients with EZH2 mutations should be treated with immunotherapy carefully (67–69). This evidence concerns the gene CD274 and neoplasm.